logo
Share SHARE
FONT-SIZE Plus   Neg

ACHN Soars On PNH Data, ACAD Abuzz, ALDR On Track, Zealand To Debut On Nasdaq

Pharma-080817-lt.jpg

Today's Daily Dose brings you news about Achillion's phase II trial results of ACH-4471 in paroxysmal nocturnal hemoglobinuria; ACADIA's improving financials; Alder's near-term catalysts; Navidea's progress in its pipeline and Theravence's anticipated milestones.

Read on...

Shares of Achillion Pharmaceuticals Inc. (ACHN) were up more than 27% in extended trading on Tuesday, following encouraging interim results from a phase II trial of ACH-4471 in patients with untreated paroxysmal nocturnal hemoglobinuria, or PNH.

According to the Company, interim trial results in four patients demonstrate ability of ACH-4471 to reduce LDH and improve hemoglobin and fatigue scores in patients with untreated PNH. Patients with PNH have elevated levels of lactate dehydrogenase (LDH).

ACHN closed Tuesday's trading at $4.01, up 1.01%. In after-hours, the stock was up 27.68% to $5.12.

ACADIA Pharmaceuticals Inc. (ACAD) reported a narrower loss for the second quarter of 2017 on higher net product sales.

For the three months ended June 30, 2017, the Company's net loss shrunk to $67.4 million or $0.55 per share from $71.3 million or $0.63 per common share for the same period in 2016.

Net product sales of NUPLAZID, which was first made available for prescription starting in May 2016, were $30.5 million for the recent second quarter, up from $0.1 million in the comparable year-ago quarter.

ACAD closed Tuesday's trading at $29.54, down 3.37%. In after-hours, the stock was up 13.07% to $33.40.

Aeterna Zentaris Inc.'s (AEZS) Strategic Review Committee, which has been formed to consider and evaluate various strategic and financing alternatives to maximize shareholder value, has engaged a consulting firm and a financial advisor to assist in its efforts.

Last month, the Company appointed Michael Ward as the Chief Executive Officer, replacing David Dodd.

AEZS closed Tuesday's trading at $1.82, down 4.21%.

Alder BioPharmaceuticals Inc. (ALDR) is on track to complete enrollment in PROMISE 2, the second pivotal phase III study of Eptinezumab that focuses on chronic migraine, in the second half of 2017.

On June 27, 2017, Alder reported positive results from its phase III pivotal clinical trial of Eptinezumab for migraine prevention, dubbed PROMISE I.

Additional data from the Eptinezumab program are anticipated to be presented at the 18th Congress of the International Headache Society, to be held September 7-10, 2017.

ALDR closed Tuesday's trading at $9.20, down 2.65%. In after-hours, the stock gained 7.61% to $9.90.

Navidea Biopharmaceuticals Inc. (NAVB) has a couple of events to watch out for in the coming months.

The Company expects enrollment in its phase 1/2 trial evaluating the use of Tc-99m Tilmanocept, to diagnose rheumatoid arthritis and distinguish it from other types of inflammatory arthritis, in the fourth quarter of 2017.

Interim results from an imaging study of Tc 99m Tilmanocept in patients with colorectal cancer and liver metastases are expected by year-end.

NAVB closed Tuesday's trading at $0.39, down 5.97%. In after-hours, the stock was up 2.21% to $0.40.

Theravance Biopharma Inc. (TBPH) has a couple of events lined up for the coming months.

The New Drug Application for Revefenacin for the treatment of chronic obstructive pulmonary disease (COPD) is expected to be filed in the fourth quarter of this year.

A phase IIIb study comparing once daily nebulized Revefenacin with Spiriva once daily delivered via the HandiHaler on lung function in subjects with COPD and a Low Peak Inspiratory Flow Rate is expected to be completed in the first quarter of 2018.

A phase III study of Closed Triple (the triple combination therapy of fluticasone furoate, umeclidinium, and vilanterol in a single ELLIPTA inhaler) in COPD patients is underway, with results expected this year.

A phase III study of the Closed Triple in patients with asthma, dubbed CAPTAIN, is scheduled for completion in 2018.

Data from remaining cohorts of Phase 1b study of TD-1473 in patients with ulcerative colitis are expected to be released in 2018 and data from Phase 2a study of TD-9855 in patients with neurogenic orthostatic hypotension are slated for release in first half of 2018.

In related news, the Company reported encouraging data from the first cohort of patients in Phase 1b study of TD-1473 in patients with ulcerative colitis.

TBPH closed Tuesday's trading at $29.79, down 0.23%.

The American Depositary Shares of Zealand Pharma A/S are expected to begin trading on the Nasdaq Global Select Market under the symbol "ZEAL" on August 9, 2017.

A total of 4.37 million American Depositary Shares and a corresponding number of underlying new shares are being issued in the offering at a public offering price of $17.87 per American Depositary Share, corresponding to a subscription price of DKK 112.58 per underlying share.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

comments powered by Disqus
Follow RTT